Insitu Biologics is a clinical stage pharmaceutical company that is developing a disruptive technology for the treatment of post operative pain management. Post operative pain is one of the leading reasons physicians prescribe opioids and a significant factor in the current opioid crisis in the U.S. InSitu controls pain with one peripheral nerve block injection that provides 5 days of pain management with no opioids. At the end of the treatment period most patients can transition directly to ibuprophen or some other OTC pain medication. This extended relief platform offers new hope to the over 21 million surgical patients whose only other option is opioid treatment. InSite has more than 20 patents on its product and process for the precision delivery of the pain medication. This platform technology also has significant opportunities in cancer, anti-inflammatory and antibiotic drug delivery.